UBS Group
ALNY icon

UBS Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,988
Closed -$989K – 10419
2026
Q1 		$989K Sell
2,988
-6,000
-67% -$2.04M ﹤0.01% 5567
2025
Q4 		$3.57M Buy
8,988
+6,000
+201% +$2.66M ﹤0.01% 4366
2025
Q3 		$1.36M Sell
2,988
-12,500
-81% -$5.09M ﹤0.01% 5303
2025
Q2 		$5.05M Buy
+15,488
New +$4.29M ﹤0.01% 3869
2024
Q2 		– Sell
-10,000
Closed -$1.49M – 9482
2024
Q1 		$1.49M Buy
10,000
+2,200
+28% +$367K ﹤0.01% 4232
2023
Q4 		$1.49M Buy
+7,800
New +$1.33M ﹤0.01% 4119
2023
Q2 		– Sell
-2,000
Closed -$401K – 8851
2023
Q1 		$401K Hold
2,000
– – ﹤0.01% 4864
2022
Q4 		$475K Buy
+2,000
New +$427K ﹤0.01% 4757
2019
Q1 		– Sell
-34,700
Closed -$2.53M – 7695
2018
Q4 		$2.53M Buy
+34,700
New +$2.67M ﹤0.01% 2804
2017
Q4 		– Sell
-71,000
Closed -$8.34M – 7818
2017
Q3 		$8.34M Sell
71,000
-55,000
-44% -$4.69M ﹤0.01% 1756
2017
Q2 		$10.1M Buy
+126,000
New +$8.05M 0.01% 1539
2015
Q4 		– Sell
-50,800
Closed -$4.08M – 8309
2015
Q3 		$4.08M Buy
50,800
+50,000
+6,250% +$5.56M ﹤0.01% 2088
2015
Q2 		$96K Sell
800
-100
-11% -$11.9K ﹤0.01% 5437
2015
Q1 		$94K Buy
900
+400
+80% +$40.5K ﹤0.01% 5457
2014
Q4 		$49K Buy
+500
New +$46.3K ﹤0.01% 6502

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ALNY Position: Q2 2026 in Review

UBS Group increased its Alnylam Pharmaceuticals (ALNY) stake by 37% in Q2 2026, buying an estimated $50.7M and bringing the position to 627,004 shares worth $189M. The position accounts for 0.02% of the portfolio, ranked #699.

UBS Group first reported a position in ALNY in Q4 2014 and has held it in 47 quarters since. The position peaked at $328M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • UBS Group held 627,004 shares of Alnylam Pharmaceuticals worth $189M as of Q2 2026.
  • UBS Group bought 168,134 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $50.7M.
  • Alnylam Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #699 holding.
  • UBS Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Alnylam Pharmaceuticals position peaked at $328M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.